Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
$71.42+6.25%
报价 2026-11-06
市值
$479.4M
EV
$673.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -42.3%
$50.12$123.84
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MNPRMonopar Therapeutics Inc. | $479.4M | +6.2% | – | 0% | – | – | – | |
| OMEROmeros Corporation | $1.22B | -0.9% | +2728.0% | 95.8% | 9.7x | 10.7x | – | |
| LXRXLexicon Pharmaceuticals, Inc. | $792M | +10.6% | -19.6% | 98.6% | – | – | – | |
| FDMT4D Molecular Therapeutics, Inc. | $676.7M | +8.9% | -67.5% | 42% | – | – | – | |
| FULCFulcrum Therapeutics, Inc. | $282.3M | +0.5% | -98.9% | 0% | – | – | – | |
| BCYCBicycle Therapeutics plc | $253M | +3.7% | – | 100% | – | – | – | |
| CMPXCompass Therapeutics, Inc. | $136.7M | +10.8% | -125.5% | 0% | – | – | – | |
| AKBAAkebia Therapeutics, Inc. | $111.2M | -5.7% | -5.1% | 79.5% | – | – | 4.9x | |
| NMRANeumora Therapeutics, Inc. Common Stock | $94.6M | +3.3% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -43.5% | 60.7% | 9.7x | 10.7x | 4.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。